Pompe Disease Market


Pompe Disease Market Insights, Epidemiology and MarketForecast-2028 report by DelveInsight provides an in-depth understanding of the disease, historical & forecasted epidemiology as well as Pompe Disease market trends in the United States, EU5 (Germany, Spain, Italy, France and the United Kingdom), and Japan.
Pompe disease, also known as glycogen storage disease type II [GSDII], acid maltase deficiency or GAA deficiency), an autosomal recessive inherited disorder caused by a mutation in the GAA gene.
GAA Deficiency affects lysosomal-mediated degradation of glycogenesis and leads to intralysosomal glycogen accumulation and disruption of the tissue architecture in various organs, like in skeletal muscles, heart and liver.

Pompe Disease epidemiology division proffers the insights about historical and current patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
All forms of Pompe disease prevalence is estimated to be 1 in 40,000. The disease affects males and females equally. The Pompe disease classification is based on the age of onset, organ involvement, severity, and the rate of disease progression. Three major forms of GSD II are recognized: classic infantile-onset, a non-classic variant of infantile-onset, and late-onset (includes childhood, juvenile, and adult-onset).
IOPD (infantile-onset Pompe disease) associated with cardiomyopathy is referred to as classic Pompe disease and in the absence of cardiomyopathy as non-classic Pompe disease. The diagnosed incidence of Classic IOPD and Non-Classic IOPD in the United States were 635 and 109 respectively in 2017.
Pompe disease Epidemiology is estimated to be 1:40,000 live births with the late-onset form of the disease generally being more common than the early neonatal form.  The disease has a variation between various ethnic groups, with African-Americans having Pompe Disease incidence as 1:14,000.  Pompe disease prevalence is approximately 1 in 28,000 in the United States. The total diagnosed Pompe Disease prevalent population in the United States shall grow at a CAGR of 0.48% for the study period of 2017 to 2028.


Comments

Popular posts from this blog

Cyclin-dependent kinase

Tenosynovial Giant Cell Tumors (TSGCTs) Market Research Report 2030 | Tenosynovial Giant Cell Tumors (TSGCTs) Market

Smoking Cessation Market Research Report 2030 | Smoking Cessation Market